Immune responses that are associated with a decreased risk of infection are called correlates of protection (CoP). Clinical trials that measure vaccine-induced antibody and cell-mediated immune responses help to define CoP to HIV, which are necessary to assess the efficacy of a promising HIV vaccine candidate. A pilot study led by senior authors Georgia Tomaras and Peter Gilbert and first authors Scott Neidich, Youyi Fong and Shuying Li of the NIAID-funded HIV Vaccine Trials Network (HVTN) demonstrated that an increase in three antibody-mediated immune responses (antibody-mediated Fcƴ receptor [FcgR] recruitment, antibody-dependent cellular phagocytosis [ADCP], and anti-Env IgG3) correlated with a decrease in HIV transmission. Read more >
An early phase study was conducted in the U.S. in which different combinations of DNA (DNA-HIV-PT123) and protein (AIDSVAX® B/E) vaccines were administered in four randomized treatment groups (T1, T2, T3, T4), to determine which strategy would induce favorable HIV-specific antibody and T-cell responses. The study led by protocol co-chair and Investigator at the Emory Center for AIDS Research Nadine Rouphael, M.D. and chair and professor in the Department of Medicine at the University of Rochester Medical Center Michael Keefer, M.D. demonstrated that DNA (DNA-HIV-PT123) and protein (AIDSVAX® B/E) combination vaccine regimens induced high magnitude and long-lasting binding antibody responses and that more rapid potentially protective immune responses were observed when the vaccine regimens were co-administered. The “DNA priming and gp120 boosting induces HIV-specific antibodies in randomized clinical trial” findings were published in The Journal of Clinical Investigation on September 30. Read more >
The results of the study called HVTN 097, titled “Immune correlates of the Thai RV144 vaccine regimen in South Africa” and led by Dr. Glenda Gray, Co-Principal Investigator of the HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and President of the South African Medical Research Council (SAMRC), were published in the journal Science Translational Medicine on September 18. This study was conducted in South Africa using the same HIV vaccine regimen that showed modest protection in an efficacy study conducted in Thailand, where clades B and E are prominent. Although clade C is the dominant circulating strain of HIV in South Africa, the RV144/Thai vaccine regimen mounted significant cellular and antibody responses in study participants enrolled in South Africa. Read more >
An international consortium that includes Seattle’s Fred Hutchinson Cancer Research Center will begin recruiting thousands of volunteers on three continents in late 2019 for a trial of a vaccine designed to protect people against multiple strains of HIV.
The new trial announced on July 16 is called Mosaico and was described as a “complementary study” to an ongoing one among women in Africa. Consortium members will discuss the trial next week at the 10th International AIDS Society Conference on HIV Science taking place July 21–24 in Mexico City. Read more >
Approximately 55 clinical research sites in South America, the U.S. and Europe, are geared to participate in a new large-scale HIV vaccine efficacy clinical trial, called Mosaico (HVTN 706/HPX3002). At the upcoming 10th IAS Conference on HIV Science (IAS 2019) taking place July 21-24 in Mexico City, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, and a global consortium of partners will describe how the next candidate preventive HIV vaccine regimen will move forward in a clinical trial to test its efficacy among cisgender men and transgender people who have sex with men. Study teams will seek to enroll 3,800 healthy HIV negative at-risk study participants between the ages 18 – 60 years who would benefit most from a preventive HIV vaccine – those without an existing highly effective HIV prevention strategy. The randomized, double-blind, placebo-controlled trial is expected to get underway later this year. Read more >
The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. The clinical trials, underway on four continents in 12 countries, are made possible by 12,669 study participants and the collaborative efforts of HVTN study teams, all on a journey to find a safe and effective HIV vaccine. Complete enrollment facilitates the collection and analysis of trial-specific data, enabling researchers to answer research questions. Read more >
Now Available: The Latest Issue of Community Compass
June 18, 2019
Ways to measure exposure to HIV could be important in helping identify those at the greatest risk of acquiring the virus, improving the design of future HIV prevention efficacy trials and public health interventions. In a recent study, conducted by the HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, researchers evaluated the use of self-administered daily vaginal swabs to detect HIV in conjunction with a mobile phone survey. Read more >
HIV Vaccine Trials Network (HVTN) set to engage communities at 9th SA AIDS Conference – Durban, South Africa.
Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and headquartered at the Fred Hutchinson Cancer Research Center, the HVTN will join study participants, communities and in-country partners to talk about its four large-scale HIV vaccine efficacy clinical trials that are fully enrolled or nearing full enrollment. These large-scale HIV vaccine efficacy clinical trials are underway in the conference host country, South Africa, and in 11 other countries across four continents. Read more >
As thousands of researchers from around the globe converge on Seattle for a conference on HIV/AIDS, top health officials in the United States are preparing to launch an ambitious new program aimed at eliminating new infections in the U.S. by 2030.
In advance of the Conference on Retroviruses and Opportunistic Infections, or CROI, which opened today at the Washington State Convention Center, Dr. Carl Dieffenbach, who heads AIDS research for the National Institutes of Health, said that the NIH has the money it needs “to jumpstart the program in this fiscal year” and continue it through the next one. Read more >
An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports. Read more >
HVTN and its partners are conducting two large-scale clinical trials evaluating the safety and efficacy of experimental HIV vaccine regimens as part of a global response to the HIV and AIDS epidemic. One of these trials, called HVTN 702, was launched in November 2016 in South Africa and has enrolled 4,611 of 5,400 study participants (85 percent). The second study, called Imbokodo or HVTN 705/HPX2008, recently reached 53 percent enrollment, having enrolled 1,384 of 2,600 women in southern Africa since its launch in November 2017. Read more >
'Cautiously optimistic' about HIV vaccines
November 30, 2018
When World AIDS Day was first observed 30 years ago, Dr. Larry Corey was already in the thick of it, a scientific leader in the struggle to tame a pandemic that has now taken 35.4 million lives. Today, the former president and director of Seattle’s Fred Hutchinson Cancer Research Center continues to lead international efforts to stop HIV/AIDS, focused on the search for an effective vaccine.
News Release: 15th Annual Stronger Together World AIDS Day breakfast
November 30, 2018
Now Available: The Latest Issue of Community Compass
November 21, 2018
Results from a meta-analysis combining information from a variety of nonhuman primate SHIV (simian/human immunodeficiency virus) challenge studies suggest that the concentration of neutralizing HIV antibodies in the bloodstream correlates strongly to protection against SHIV infection. Read more >
Scientific presentations by the HIV Vaccine Trials Network (HVTN) at the HIV Research for Prevention (HIVR4P) conference showed promising early-stage clinical findings that advance the development of DNA vaccines to prevent HIV infection. Read more >
News Release: Gut microbiome may impact HIV vaccine immune responses
October 23, 2018
In a late breaker abstract presentation titled: Human gut microbiota are associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination, James Kublin M.D. of the HIV Vaccine Trials Network (HVTN) explained that the human microbiome and immune system shape each other through lifelong interactions. He and his team used 16S ribosomal RNA sequencing of stool samples to understand the role of the human gut microbiome in modulating the immune response to two experimental HIV vaccines. Read more >
“We are grateful to each study participant and their communities for making a commitment to participate in the AMP Studies”, said Larry Corey, M.D., Principal Investigator of the HVTN, virologist and faculty member at Fred Hutchinson Cancer Research Center in Seattle. “Study participants are the heartbeat of our global clinical trials”. Read more >
An HIV Vaccine Trials Network (HVTN)-funded pilot study was conducted in South Africa to test the development and implementation of a basic mobile phone-based tool to collect data from adult participants enrolled in a phase 1/2a, randomized, controlled double-blind trial called HVTN 108. Read more >
Developing an effective HIV vaccine is the “key step forward” we have been pursuing as a global community to halt one of humankind’s most formidable foes. Read more >
Researchers used a dynamic economic mathematical model to show that five-dose series HIV vaccine campaigns rolled out every two years, in the country with the highest number of daily new HIV infections (South Africa), would provide great health benefits and be potentially cost-effective. Read more >
The Nelson Mandela Academic Clinical Research Unit (NeMACRU) in Mthatha, South Africa became part of a network of clinical trial sites that are conducting the largest Phase 2b/3 HIV vaccine efficacy clinical trial in the country. Read more >
An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection. Read more >
The pride of Fred Hutch
June 7, 2018
Steven Wakefield of the HIV Vaccine Trials Network and Fred Hutchinson Cancer Research Center will be one of five grand marshals in the 2018 Seattle Pride Parade on June 24, an honor that is especially fitting given this year’s theme, “Pride Beyond Borders.”
HIV Vaccine Science, Research, Updates and Advocacy
May 31, 2018
Neither frequency of alcohol use, binge drinking, marijuana, nor other drug use negatively impacts retention and adherence rates in phase I clinical trials of preventive HIV vaccines. Read more >
HVTN Media Room
May 23, 2018
Now Available: The Latest Issue of Community Compass
May 21, 2018
The Rise of Broadly Neutralizing Antibodies
May 17, 2018
March 8, 2018
25 powerful years of HIV research
February 26, 2018
Microbiome research refines HIV risk for women
January 25, 2018
Meet Peru's HIV Superhero
January 22, 2018
Reflections on Bonnie Mathieson
January 11, 2018
Everyone who ever met Bonnie Mathieson had to be taken in with her smile, her enthusiasm for science, her great questions at meetings, and her keen perceptions about HIV and the field of HIV vaccines. We in the HIV Vaccine Trials Network (HVTN) community owe enormous thanks and gratitude for her support and guidance since the advent of our organization 17 years ago.
10 highlights of Fred Hutch science in 2017
December 28, 2017
Dr. Gregory Wilson
December 27, 2017
Part 5/5: New 'mosaic' HIV vaccine study launched for World AIDS Day
December 1, 2017
World AIDS Day Message
December 1, 2017
As we arrive at another World AIDS Day, more than 30 years after the start of this epidemic, we fortunately stand in a very different place than in prior years. Major strides in HIV therapy continue and more than 25 million people are now on antiretroviral therapy for HIV; a remarkable achievement - one that means the life expectancy of each of these individuals can be increased over 40 years longer than a decade ago.
Now Available: Latest Issue of Community Compass
December 1, 2017
NIH and Partners Launch HIV Vaccine Efficacy Study
November 30, 2017
The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection. The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent occurred in eastern and southern Africa, with women and girls disproportionately affected.
Part 4/5: A voice for HIV cure
November 29, 2017
Part 3/5: Insights from infants could inform HIV vaccine design
November 27, 2017
Part 2/5: Enlisting the microbiome in the quest for an AIDS vaccine
November 22, 2017
Part 1/5: Understanding HIV’s evolutionary past — and future
November 20, 2017
Science Spotlight: Two is better than one
November 20, 2017
Human immunodeficiency Virus (HIV) continues to be a major public health problem. Throughout the years, there have been a multitude of vaccine trials, nearly all with mixed results. Currently, the HIV vaccine field is focused on producing protective antibodies; however, T cell responses likely contribute to protection and aid in B cell activation.
Good News at Fred Hutch
September 29, 2017
Kyle Rybczyk is the clinic coordinator for the Vanderbilt HIV Vaccine Program, a unit of the HIV Vaccine Trials Network, or HVTN. Headquartered at Fred Hutch, HVTN is the world’s largest international collaboration focused on developing vaccines to prevent HIV/AIDS. It takes a global village to run a clinical trial like the AMP HIV Prevention Study underway now. Here is one villager’s story.
A performer and HIV advocate in Nashville, Tennessee, T.K. “Thunder Kellie” Hampton works for Street Works, an HIV services organization and a key partner of the Vanderbilt University unit of the Fred Hutch-based HIV Vaccine Trials Network. He recently appeared in a musical he wrote and directed, "YOU Shall LHiV 2 Zero," at the U.S. Conference on AIDS.
Will the flu vaccine work for you? Answer may be in your genes
August 31, 2017
New nanoparticles make targeted, temporary gene therapy possible
August 30, 2017
Scientists seeking a simple and gentle way to provide short-term gene therapy have a new tool: nanoparticles. In a paper published August 30 in Nature Communications, Dr. Matthias Stephan at Fred Hutchinson Cancer Research Center describes nanoparticles he has developed that can streamline the delivery of bundled genetic material to specific cells.
Looking for ‘a multitude of ways to cure HIV’
August 21, 2017
Pioneering CAR T-cell therapy researcher Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania's Perelman School of Medicine and a co-director of the Parker Institute for Cancer Immunotherapy, delivered the keynote address at the Conference on Cell and Gene Therapy for HIV Cure at Fred Hutch. To his right is gene therapy and stem cell transplant specialist Dr. Hans-Peter Kiem, co-director of the Fred Hutch-based defeatHIV.
University of Pennsylvania immunotherapy researcher Dr. Carl June, who led the development of an experimental therapy for advanced childhood leukemia that is expected to become the first CAR T-cell therapy to win U.S. Food and Drug Administration approval, will give the keynote talk today at the Conference on Cell & Gene Therapy for HIV Cure at Fred Hutchinson Cancer Research Center.
As community engagement manager at the Vanderbilt HIV Vaccine Program, Sorrell gives talks like this many times. But even 36 years into the pandemic, HIV can make for a difficult conversation, one the 39-year-old Sorrell tailors to the audience and the moment, speaking from his heart and trusting he’ll strike the right chord.
Scared — and brave
June 14, 2017
How do people with HIV feel about volunteering for clinical trials testing experimental cures? If their responses could be summed up in one phrase, it would be the quote that Laurie Sylla chose for the title of her recent talk on the topic: “We’re scared … and brave.” Sylla is a member of the community advisory board for defeatHIV, based at Fred Hutchinson Cancer Research Center, one of six such research groups funded by the National Institutes of Health focused on curing the chronic viral infection.
Training tomorrow's HIV researchers
June 12, 2017
When Dr. Nishila Moodley took the stage to receive a special achievement award, 700 scientists, clinicians, outreach specialists and community members attending the annual meeting of the HIV Vaccine Trials Network — the largest global network working to develop and test a preventive HIV vaccine — cheered her accomplishment. They also celebrated the future of HIV vaccine research in South Africa.
eThekwini CAPRISA Research Clinic Site Profile
May 12, 2017
The Centre for the AIDS Programme of Research in South Africa(CAPRISA) conducts research that is globally relevant and locally responsive, contributing to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care. Collaboration with the HVTN to find a safe, effective HIV vaccine is integral to this work.
Dr. Glenda Gray among Time magazine’s ‘100 most influential’
April 20, 2017
Dr. Julie Overbaugh has long been committed to mentorship and graduate student training. These values have inspired the Fred Hutchinson Cancer Research Center HIV researcher and Human Biology Division member over the past year as she settled into the newly created role of Hutch Associate Director for Graduate Education.
'As Natives, it's what we do'
March 23, 2017
A Fred Hutch and University of Washington team of virologists and bioengineers led by Dr. Keith Jerome has received a $200,000 grant — the first phase of up to $1.5 million in milestone-driven funding over four years — to develop nanocarrier technology to deliver therapies to reservoirs of dormant, HIV-infected cells.
A decade has passed since the first of two stem cell transplants cured Brown of both leukemia and HIV, making him the first and so far only person to be cured of the virus that causes AIDS. Sunday’s “birthday” celebration, a tradition among transplant cancer survivors, capped a day-long workshop on HIV cure research on the eve of a major HIV scientific meeting, the annual Conference on Retroviruses and Opportunistic Infections, or CROI, being held in Seattle.
February 7, 2017
A decade after the first and so far only known HIV cure, researchers are hard at work to find a cure for many more.
It’s a tradition to celebrate the anniversary of a lifesaving bone marrow transplant as a rebirth. By that measure, today marks the 10th “birthday” of one of the world’s best known transplant survivors: Timothy Ray Brown.
Dr. Larry Corey: 35 Years in the AIDS Trenches
June 13, 2016
Today the founder and leader of the world’s largest HIV vaccine network, Corey will deliver a plenary talk on the state of HIV vaccine development at next month’s AIDS 2016 conference, the biannual meeting of the International AIDS Society, in Durban, South Africa. In August, he will be the keynote speaker at the third Conference on Cell and Gene Therapy for HIV cure at Fred Hutch about an even more challenging goal: an HIV cure.
Getting malaria on purpose
April 25, 2016
April 7, 2016
First Study to Evaluate Efficacy of Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among At Risk Populations
Super survivors: What those with HIV who don’t get sick can teach us
December 14, 2015
7 Myths About HIV and the Facts You Need to Know
November 17, 2015
Charlie Sheen reveals he’s HIV positive
November 17, 2015